速递｜减重效果显著优于司美格鲁肽！四环医药旗下惠升生物GLP-1R/GCGR创新药获批IND

Core Insights - The article discusses the recent announcement by Four Rings Pharmaceuticals regarding the IND approval for its innovative drug P052 injection, which targets both GLP-1 and GCGR receptors for the treatment of type 2 diabetes and obesity [2][4]. Group 1: Drug Development and Approval - Four Rings Pharmaceuticals' subsidiary, Huisheng Biopharmaceuticals, has received implicit approval from the NMPA for the clinical trial of P052 injection, which is designed to treat type 2 diabetes and obesity [2]. - P052 injection shows similar blood sugar-lowering effects to the GLP-1 single-target drug semaglutide, but with significantly better weight loss results [2]. Group 2: Market Potential - The GLP-1R/GCGR dual-target drug represents an innovative direction in the GLP-1 drug field, with substantial market potential. The International Diabetes Federation (IDF) projects that the number of adult diabetes patients in China will reach 148 million by 2024 and increase to 168.3 million by 2050 [4]. - The adult overweight and obesity rate in China has surpassed 50%, and if not effectively controlled, it is expected to reach 70.5% by 2030 [4]. - Novo Nordisk reported global sales of semaglutide injection at 101.4 billion Danish Krone (approximately 15.9 billion USD) in the first half of 2025, with a 15% year-on-year growth for diabetes indications and a 78% increase for weight loss indications [4]. Group 3: Company Focus - Huisheng Biopharmaceuticals is strategically focusing on the diabetes sector, with its semaglutide injection application for market approval recently accepted by the NMPA for improving blood sugar control in adults with type 2 diabetes [6]. - The semaglutide injection for weight loss has completed Phase III clinical enrollment and is currently in the follow-up stage [6].